What Is Nucynta Used For? FDA-Approved Uses

The FDA label says: “NUCYNTA ER (tapentadol) is indicated for the management of: Severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids; Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an opioid analgesic and that cannot be adequately...”

Run it in Rivvi

Which 2027 plans near you dropped or restricted Nucynta?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Nucynta, tablet, film coated, extended release

Indications and Usage, quoted from the label by Collegium Pharmaceutical, Inc. (NDA200533). Cross-references to other label sections are left out.

NUCYNTA ER (tapentadol) is indicated for the management of:
Severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.
Limitations of Use
Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including NUCYNTA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
NUCYNTA ER is not indicated as an as-needed (prn) analgesic.

Source: DailyMed label, set id c3d04d70-0155-4147-9ce4-a3b1fad4b373, version 8, effective December 30, 2025. NDC 24510-058, one of 5 listings for this product.

Nucynta, tablet, film coated

Indications and Usage, quoted from the label by Collegium Pharmaceutical, Inc. (NDA022304). Cross-references to other label sections are left out.

NUCYNTA (tapentadol) tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults and pediatric patients aged 6 years and older with a body weight of at least 40kg.
Limitations of Use
Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dose or duration, and persist over the course of therapy, reserve opioid analgesics, including NUCYNTA tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

Source: DailyMed label, set id 80938c30-9fe3-4c7d-9d9c-5476638cfb2d, version 7, effective December 30, 2025. NDC 24510-050, one of 3 listings for this product.

Questions

What is Nucynta used for?

The FDA label says: “NUCYNTA ER (tapentadol) is indicated for the management of: Severe and persistent pain in adults that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids; Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an opioid analgesic and that cannot be adequately...”

What drug class is Nucynta?

FDA lists tapentadol in the Opioid Agonist established pharmacologic class.

Does this page cover off-label uses or dosing?

No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.